Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of PCI
  • All clinical trials of immediate systematic ballon angioplastyte
    		•  

    TAMI 1 pilot study, 1987

    Treatments

    Studied treatment Angioplasty within 120 min (after rtPA)
    Control treatment defered CA (7-10 days) and angioplasty if indicated
    Concomittant treatment rtPA or placebo

    Patients

    Patients patients with acute myocardial infarction.
    Inclusion criteria patent vessel, stenosis >50%, delay from symptoms < 6h
    Exclusion criteria multivessels or diffuse lesions

    Method and design

    Randomized effectives 99 / 98 (studied vs. control)
    Design parallel group
    Blinding open
    Follow-up duration in hospital
    Number of centre 15
    Geographic area USA
    Primary endpoint LV function


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    In-hospital death

    4 / 99
         15 / 98
         0,26 [0,09;0,77]

    CABG

    15 / 99
         15 / 98
         0,99 [0,51;1,91]

    Reocclusion

    11 / 99
         13 / 98
         0,84 [0,39;1,78]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    In-hospital death 4 / 99 (4,0%) 15 / 98 (15,3%) 0,26 [0,09;0,77]    
    CABG 15 / 99 (15,2%) 15 / 98 (15,3%) 0,99 [0,51;1,91]    
    Reocclusion 11 / 99 (11,1%) 13 / 98 (13,3%) 0,84 [0,39;1,78]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    In-hospital death 4,04% 15,31% -112,7‰
    CABG 15,15% 15,31% -1,5‰
    Reocclusion 11,11% 13,27% -21,5‰


    Reference(s)

    Trials register # NA
    • Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O'Neill WW. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.. N Engl J Med 1987 Sep 3;317:581-8
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend